JBIOJade Biosciences, Inc.

HealthcareUSD
$21.31

The financials

Jade Biosciences, Inc. by the numbers

Jade Biosciences, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$59M−$28Mn/a
Net income−$56M−$32Mn/a
Diluted EPS−$0.76−$0.86n/a

Biotechnology

Ranks #55 of 145 by Smart Score

Compare peers
IMTX-4.9%
Immatics N.V.
COAG-3.6%
Hemab Therapeutics Holdings, Inc.
AVLN-3.7%
Avalyn Pharma Inc.
DMRA+2.6%
Damora Therapeutics, Inc.
INBX+0.18%
Inhibrx Biosciences, Inc.
NVAX-3.8%
Novavax, Inc.